uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
fast track
Advertisement
Leads Biolabs Gains Japan Orphan Drug Designation for Opamtistomig
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
Alume Biosciences Gains FDA Breakthrough Therapy Designation for Bevonescein
SAN DIEGO, Calif. — September 25, 2026 Alume Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Quoin Gains FDA Fast Track for QRX003 in Peeling Skin Syndrome
ASHBURN, Va. — September 22, 2026 Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast...
MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
Advertisements
Ophirex Publishes Phase 2 BRAVIO Varespladib Data
Durham, North Carolina — September 22, 2026 Ophirex announced publication of results from the Phase 2 BRAVIO clinical trial...
Arcturus to Present ARCT-810 Phase 2 OTC Deficiency Data
SAN DIEGO — September 18, 2026 Arcturus Therapeutics announced plans to provide an update on its ARCT-810 Phase 2...
PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
Beacon Therapeutics Reports Positive VISTA Data for Laru-zova
LONDON and CAMBRIDGE, Mass September 21, 2026 — Beacon Therapeutics announced positive topline results from the pivotal VISTA trial...
MAIA Biotechnology Doses First U.S. Patient in THIO-101
CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...
Advertisement
